Abstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women at reproductive age, which is characterized by obesity, hyperandrogenemia, and insulin resistance (IR). This study aimed to investigate the vitamin D status, and analyze the relationship between vitamin D deficiency and metabolic risk factors in PCOS women in Shaanxi China.
Methods: A cross-sectional study included 169 women diagnosed with PCOS and 114 control women without PCOS. The serum 25(OH)D and metabolic markers were measured. Vitamin D deficiency was defined as serum 25(OH)D concentration less than 20 ng/mL. The primary outcome was the difference in vitamin D status between the PCOS and control groups, the secondary outcomes were correlations between serum 25(OH)D concentration and metabolic risk factors in women with PCOS.
Results: The serum 25(OH)D concentration was significantly lower in women with PCOS than in controls (P < 0.05), and the prevalence rates of 25(OH)D deficiency and insufficiency were significantly higher in women with PCOS than in controls (P < 0.05). The serum 25(OH)D concentration was significantly lower in PCOS women with obesity or IR than in women without obesity or IR (P < 0.05), and the prevalence of 25(OH)D deficiency in PCOS women with obesity or IR was significantly higher than in women without obesity or IR (P < 0.05). Serum 25(OH)D concentration was significantly negatively correlated with body mass index (BMI), waist-to-hip ratio (WHR), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-sensitivity C-reactive protein (hs-CRP) (P < 0.05). In comparison, serum 25(OH)D concentration was significantly positively correlated with high-density lipoprotein cholesterol (HDL-C) (P < 0.05). Increased BMI and WHR, high levels of fasting insulin, HOMA-IR, total cholesterol, LDL-C and hs-CRP were regarded as risk factors, but high level of HDL-C was considered to be protective factor of vitamin D deficiency in PCOS women.
Conclusions: Vitamin D deficiency is prevalent in PCOS women in Shaanxi China, especially in those with obesity and IR. The serum 25(OH)D level was correlated with metabolic risk factors in PCOS women. Multi-center randomized controlled trials with large sample sizes are needed to probe the metabolic effect of vitamin D supplementation in PCOS women.
Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women at reproductive age, the prevalence of PCOS ranging from 9 to 18% (1, 2). Obesity, hyperandrogenemia, and insulin resistance (IR) are prevalent characteristics of PCOS (3). Studies have confirmed that PCOS is related to type 2 diabetes mellitus (T2DM), cardiovascular disease and metabolic syndrome (4, 5). A meta-analysis showed that 30–40% of women diagnosed with PCOS accompany IR and compensatory hyperinsulinaemia, and that ~10% of these women will develop T2DM (6). Furthermore, PCOS women were vulnerable to present with dyslipidaemia, such as higher concentrations of triglycerides (TGs) and low-density lipoprotein cholesterol (LDL-C), and lower high-density lipoprotein cholesterol (HDL-C) than healthy women (7).
It is known that vitamin D regulate the skeletal growth and development and calcium/phosphorus metabolism. Nevertheless, vitamin D also is related to other diseases, including immune disorders (8), T2DM (9), cardiovascular disease (10), infectious diseases, and cancer (11). In recent years, the difference of vitamin D levels between PCOS women and healthy women, the relationship between vitamin D and metabolic factors in PCOS women has remained controversial. Some studies have shown that PCOS women had lower serum 25(OH)D concentration than healthy women, and vitamin D deficiency was associated with homeostasis model assessment of insulin resistance (HOMA-IR), hyperinsulinaemia, dyslipidaemia, and metabolic risk factors in patients with PCOS (12, 13). However, other scholars have found different results (14).
Vitamin D deficiency and PCOS are associated with metabolic disorders, but little is known about vitamin D status in women with PCOS in Shaanxi China. Therefore, this cross-sectional study aims to investigate vitamin D status and analyze the relationship between vitamin D deficiency and metabolic risk factors in women with PCOS.
Materials and Methods
Study Design and Participants
This survey was a cross-sectional study. A total of 169 women diagnosed with PCOS were recruited through random sampling from five different communities in the city of Xi'an in Shaanxi, China. Participants were selected from the gynecological clinic and women's health clinic in the First Affiliated Hospital of Xi'an Jiaotong University from January 2018 to May 2019. One hundred and fourteen women without PCOS were selected as controls at the same time. The diagnostic criteria of PCOS we used were the modified Rotterdam criteria (15). Women with thyroid disease, congenital adrenal hyperplasia or autoimmune disease were excluded. The protocol was approved by the First Affiliated Hospital of Xi'an Jiaotong University Institutional Review Board.
Outcome Measures
A questionnaire was administered to each participant in a face-to-face interview. Basic information was collected, including age, body mass index (BMI), waist-to-hip ratio (WHR), and blood pressure. BMI ≥28.0 kg/m2 was defined as obesity (16). All biochemical indicators were tested in our hospital including serum 25-hydroxyvitamin D[25(OH)D], follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), testosterone (T), estradiol (E2), progesterone (P), blood glucose, insulin, blood lipids, and high-sensitivity C-reactive protein (hs-CRP). HOMA-IR was calculated to evaluate insulin resistance (IR). HOMA-IR = [fasting glucose(mmol/L) × fasting insulin(mIU/L)]/22.5. HOMA-IR > 2.5 was defined as IR (17). The serum 25(OH)D levels lower than 20 ng/mL were defined as vitamin D deficiency, and women with a concentration of 20~30 ng/mL were defined as vitamin D insufficiency. Serum 25(OH)D concentration of 30~50 ng/mL were defined as normal (18).
The primary outcome was the difference of vitamin D level between the PCOS and control groups. The secondary outcomes were correlations between serum 25(OH)D concentration and metabolic risk factors in PCOS women.
Statistical Analysis
Data in this study were analyzed using SPSS version 20.0. The continuous variables are presented as mean ± SD, which were performed by Student's t-test or variance analysis. The categorical parameters are displayed as numbers (%), which were analyzed by chi-square test. Linear regression analysis was used to analyze the correlation of 25(OH)D concentration with metabolic parameters. The relationship between vitamin D deficiency and metabolic risk factors were analyzed by multinomial logistic regression analysis. P < 0.05 was considered statistically significant.
Results
Basic Characteristic of the Studied Groups
Table 1 illustrates the baseline characteristics of women in the two groups. The BMI, WHR, and serum LH and T concentrations were significantly higher in women with PCOS than in controls (P < 0.05). No significant difference was found when comparing other baseline characteristics between the two groups (P > 0.05).
Table 1
| PCOS group (n = 169) | Control group (n = 114) | P-valuea | |
|---|---|---|---|
| Age (years)b | 28.4 ± 8.3 | 27.2 ± 7.9 | 0.872 |
| BMI (kg/m2)b | 24.7 ± 6.5 | 21.8 ± 5.6 | 0.046 |
| WHRb | 0.9 ± 0.3 | 0.7 ± 0.3 | 0.048 |
| Blood pressureb | 0.409 | ||
|  Systolic (mm Hg) | 115.6 ± 14.6 | 109.5 ± 13.8 | 0.122 |
|  Diastolic (mm Hg) | 81.2 ± 9.3 | 76.9 ± 8.5 | 0.346 |
| Outdoor exercisec | 0.302 | ||
| Â Never | 51 (30.2%) | 28 (24.6%) | |
|  ≥1 times daily | 118 (69.8%) | 86 (75.4%) | |
| Marital statusc | 0.213 | ||
| Â Single | 45 (26.6%) | 23 (20.2%) | |
| Â Married | 124 (73.4%) | 91 (79.8%) | |
| Basal concentrationb | |||
|  FSH (mIU/mL) | 6.8 ± 1.7 | 7.4 ± 1.8 | 0.457 |
|  LH (mIU/mL) | 12.5 ± 3.2 | 9.3 ± 2.8 | 0.032 |
|  PRL (ng/mL) | 15.4 ± 5.8 | 13.5 ± 4.2 | 0.053 |
|  E2 (pmol/L) | 89.1 ± 16.4 | 79.5 ± 14.1 | 0.179 |
|  T (nmol/L) | 1.9 ± 0.8 | 1.4 ± 0.6 | 0.042 |
| Time of blood detectionc | 0.701 | ||
| Â Spring | 36 (21.3%) | 29 (25.4%) | |
| Â Summer | 52 (30.8%) | 34 (29.8%) | |
| Â Autumn | 43 (25.4%) | 31 (27.2%) | |
| Â Winter | 38 (22.5%) | 20 (17.5%) |
Baseline characteristics of women between the two groups.
T-test or chi-square test.
Data are presented as mean ± SD.
Data are presented as number(%).
Vitamin D Status Between PCOS Women and Controls
The serum 25(OH)D concentration was significantly lower in PCOS women than in controls (11.6 ± 7.2 vs. 18.9 ± 8.4 ng/mL, P < 0.05) (Figure 1A). In addition, the prevalence rates of 25(OH)D deficiency and insufficiency were significantly higher in women with PCOS than in controls (54.4% vs. 37.7%, P < 0.01; 34.9% vs. 23.7%, P < 0.05). Furthermore, the prevalence of normal 25(OH)D status in women with PCOS was significantly lower than that in controls (10.7% vs. 38.6%, P < 0.01) (Figure 1B).
Figure 1
The serum 25(OH)D concentration was significantly lower in PCOS women with obesity or IR than in women without obesity or IR (8.9 ± 3.7 vs. 13.6 ± 5.3 ng/mL, P < 0.05; 7.2 ± 2.9 vs. 15.8 ± 4.9 ng/mL, P < 0.01) (Figures 2A,C). Additionally, the prevalence of 25(OH)D deficiency in PCOS women with obesity or IR was significantly higher than in women without obesity or IR (57.4% vs. 40.0%, P < 0.05; 64.4% vs. 35.3%, P < 0.01) (Figures 2B,D).
Figure 2
Table 2 shows the metabolic parameters among different vitamin D statuses in women with PCOS. There were statistically significant differences in BMI, WHR, fasting insulin, HOMA-IR, total cholesterol, LDL-C, HDL-C, and hs-CRP among the three groups (P < 0.05). No significant difference was found when comparing fasting glucose and triglycerides among different groups (P > 0.05).
Table 2
| Deficiency group (n = 92) | Insufficiency group (n = 59) | Normal group (n = 18) | P-valuea | |
|---|---|---|---|---|
| BMI (kg/m2) | 27.3 ± 9.2b | 25.4 ± 8.1 | 23.5 ± 9.3 | 0.029 |
| WHR | 1.0 ± 0.4b | 0.9 ± 0.5 | 0.8 ± 0.3 | 0.036 |
| Fasting glucose (mmol/L) | 5.1 ± 1.9 | 4.9 ± 1.6 | 4.8 ± 1.7 | 0.327 |
| Fasting insulin (mIU/L) | 39.6 ± 10.7bc | 33.5 ± 9.9d | 26.8 ± 8.5 | 0.012 |
| HOMA-IR | 8.9 ± 3.7bc | 7.3 ± 2.8d | 5.7 ± 2.1 | 0.009 |
| Total cholesterol (mmol/L) | 6.1 ± 1.7bc | 5.5 ± 1.6d | 4.2 ± 1.4 | 0.033 |
| LDL-C (mmol/L) | 2.5 ± 0.9b | 2.3 ± 0.8 | 2.0 ± 0.7 | 0.041 |
| HDL-C (mmol/L) | 1.3 ± 0.6b | 1.4 ± 0.7d | 1.8 ± 0.6 | 0.030 |
| Triglycerides (mmol/L) | 2.3 ± 0.9b | 2.1 ± 0.8d | 1.9 ± 0.8 | 0.068 |
| Apo A (g/L) | 1.3 ± 0.5 | 1.4 ± 0.7 | 1.5 ± 0.3 | 0.115 |
| Apo B (g/L) | 1.0 ± 0.4 | 0.9 ± 0.3 | 0.8 ± 0.4 | 0.632 |
| hs-CRP (mg/L) | 2.4 ± 0.9bc | 1.9 ± 0.6d | 1.4 ± 0.3 | 0.017 |
Metabolic parameters among different vitamin D status in women with PCOS.
Variance analysis.
Deficiency group vs. Normal group, P < 0.05.
Deficiency group vs. Insufficiency group, P < 0.05.
Insufficiency group vs. Normal group, P < 0.05.
Vitamin D and Metabolic Risk Factors in PCOS Women
The data in Table 3 suggest that serum 25(OH)D concentration was significantly negatively correlated with BMI, WHR, fasting insulin, HOMA-IR, total cholesterol, LDL-C and hs-CRP (P < 0.05). In comparison, serum 25(OH)D concentration was significantly positively correlated with HDL-C (P < 0.05). However, no significant correlation was found between serum 25(OH)D concentration and age, fasting glucose, triglycerides, Apo A or Apo B (P > 0.05).
Table 3
| R | P-value | |
|---|---|---|
| Age (years) | −0.089 | 0.582 |
| BMI (kg/m2) | −0.581 | 0.016 |
| WHR | −0.424 | 0.032 |
| Fasting glucose (mmol/L) | −0.246 | 0.237 |
| Fasting insulin (mIU/L) | −0.624 | 0.003 |
| HOMA–IR | −0.635 | 0.001 |
| Total cholesterol (mmol/L) | −0.426 | 0.032 |
| LDL-C (mmol/L) | −0.474 | 0.022 |
| HDL-C (mmol/L) | 0.419 | 0.043 |
| Triglycerides (mmol/L) | −0.326 | 0.108 |
| Apo A (g/L) | −0.113 | 0.567 |
| Apo B (g/L) | −0.076 | 0.683 |
| hs-CRP (mg/L) | −0.539 | 0.028 |
Correlation of serum 25(OH)D concentration with metabolic parameters in PCOS women.
The data in Table 4 suggest that increased BMI and WHR, high levels of fasting insulin, HOMA-IR, total cholesterol, LDL-C and hs-CRP were regarded as risk factors of vitamin D deficiency in women with PCOS. Additionally, outdoor exercise (≥1 times daily) and high level of HDL-C were considered to be protective factors of vitamin D deficiency in PCOS women.
Table 4
| 95.0% CI | OR | P-value | |
|---|---|---|---|
| Age (years) | |||
|  ≤ 25 | Reference | 1.00 | – |
|  26–34 | 0.48–1.91 | 1.02 | 0.692 |
|  ≥35 | 0.53–2.06 | 1.13 | 0.583 |
| BMI (kg/m2) | |||
| Â <25 | Reference | 1.00 | - |
|  ≥25 | 1.23–5.18 | 2.53 | 0.011 |
| WHR | |||
| Â <0.85 | Reference | 1.00 | - |
|  ≥0.85 | 1.17–3.92 | 2.17 | 0.019 |
| Hypertension | |||
| Â No | Reference | 1.00 | - |
|  Yes | 0.29–2.97 | 1.24 | 0.376 |
| Outdoor exercise | |||
| Â Never | Reference | 1.00 | - |
|  ≥1 times daily | 0.31–0.93 | 0.49 | 0.032 |
| Fasting glucose (mmol/L) | |||
| Â <6.1 | Reference | 1.00 | - |
|  ≥6.1 | 0.57–2.03 | 1.57 | 0.119 |
| Fasting insulin (mIU/L) | |||
| Â <20 | Reference | 1.00 | - |
|  ≥20 | 1.96–38.9 | 5.74 | 0.008 |
| HOMA-IR | |||
| Â <2.66 | Reference | 1.00 | - |
|  ≥2.66 | 2.58–73.2 | 10.06 | 0.003 |
| Total cholesterol (mmol/L) | |||
| Â <5.69 | Reference | 1.00 | - |
|  ≥5.69 | 0.93–2.86 | 1.98 | 0.047 |
| LDL-C (mmol/L) | |||
| Â <3.1 | Reference | 1.00 | - |
|  ≥3.1 | 1.88–7.43 | 2.23 | 0.035 |
| HDL-C (mmol/L) | |||
| Â <1.55 | Reference | 1.00 | - |
|  ≥1.55 | 0.25–0.89 | 0.37 | 0.024 |
| Triglycerides (mmol/L) | |||
| Â <1.47 | Reference | 1.00 | - |
|  ≥1.47 | 1.03–2.96 | 1.38 | 0.065 |
| Apo A (g/L) | |||
| Â <1.61 | Reference | 1.00 | - |
|  ≥1.61 | 0.63–2.24 | 1.48 | 0.223 |
| Apo B (g/L) | |||
| Â <1.05 | Reference | 1.00 | - |
|  ≥1.05 | 0.56–2.17 | 1.25 | 0.446 |
| hs-CRP (mg/L) | |||
| Â <3 | Reference | 1.00 | - |
|  ≥3 | 1.85–6.37 | 2.18 | 0.038 |
Multinomial logistic regression model of risk factors for vitamin D deficiency in women with PCOS.
Discussion
More than one billion children and adults are suffering from vitamin D deficiency, which is common worldwide (19). PCOS women manifest a relatively high prevalence of vitamin D deficiency than healthy women, and vitamin D deficiency is associated with ovulatory dysfunction, IR and hyperandrogenism (20). Thus, in recent years, many studies have been performed to analyze vitamin D status of PCOS women (21). Data from our study showed that the serum 25(OH)D concentration was significantly lower, and the prevalence rates of 25(OH)D deficiency and insufficiency were significantly higher in women with PCOS than in controls, the results is similar to previous study (22). It has been confirmed that PCOS women accompany vitamin D deficiency, and 67–85% of them had serum 25(OH)D level <20 ng/mL (23).
Multiple observational studies have shown that low vitamin D concentration is associated with increased BMI, IR, testosterone and dehydroepiandrosterone sulfate (DHEAS) levels in women with PCOS (24), which was consistent with our study, where we showed that serum 25(OH)D concentration was significantly lower in PCOS women with obesity or IR than in women without obesity or IR. In addition, the prevalence of 25(OH)D deficiency in PCOS women with obesity or IR was significantly higher than in women without obesity or IR. Epidemiological studies have confirmed that vitamin D status was negatively associated with diabetes, which may be related to multiple factors. Research confirmed that 25(OH)D can increase the expression of insulin receptors, and inhibit the release of inflammatory cytokines that are proved to cause IR (25). Furthermore, it has been reported that vitamin D has an indirect useful function on insulin role through regulation of extracellular calcium (26). However, other researchers have revealed different results. Ng et al. demonstrated that there was no statistically significant correlation between vitamin D level and BMI, WHR, and metabolic parameters among PCOS women (14). This difference may be explained by differences in sample size, habits of the participants, place of residence, and season of detection of vitamin D.
Concerning the lipid profile, this study demonstrated that serum 25(OH)D concentration in women with PCOS was significantly and negatively correlated with total cholesterol and LDL-C but was significantly positively correlated with HDL-C. This finding was concordant with the results of previous studies (27). It is well-known that cardiovascular disease is associated with high total cholesterol and LDL-C levels and low HDL-C levels. Therefore, vitamin D supplementation may reduce the incidence of cardiovascular disease in vitamin D-deficient women with PCOS by improving dyslipidaemia. However, the relationship between serum 25(OH)D and triglyceride concentration in PCOS women is controversial according to previous studies (28). This study demonstrated that no significant correlation was found between serum 25(OH)D concentration and triglycerides, Apo A or Apo B, which was consistent with the results of Li et al. (12).
Normal metabolism of insulin is affected by activation of inflammatory pathways. According to the published studies, the positive effects of vitamin D on sugar metabolism including regulation of insulin secretion and inhibition of proinflammatory cytokines (29). The data in our study displayed that serum 25(OH)D concentration in women with PCOS was significantly negatively correlated with hs-CRP. Results from a randomized controlled trial showed that vitamin D treatment significantly decreased serum hs-CRP in PCOS women with vitamin D deficiency (30). In addition, serum hs-CRP was improved by high dose vitamin D supplementation among PCOS women with IR (17).
Clinical manifestations of PCOS include obesity, metabolic syndrome and chronic inflammation, which are related to vitamin D deficiency (10–14, 29). Our findings revealed that serum 25(OH)D level in PCOS women was significantly negatively correlated with BMI, WHR, fasting insulin, HOMA-IR, total cholesterol, LDL-C, and hs-CRP. Additionally, serum 25(OH)D concentration was significantly positively correlated with HDL-C. Furthermore, the data from logistic regression model of risk factors for vitamin D deficiency revealed that increased BMI and WHR, high levels of fasting insulin, HOMA-IR, total cholesterol, LDL-C, and hs-CRP were regarded as risk factors of vitamin D deficiency in PCOS women. In comparison, outdoor exercise (≥1 times daily) and high level of HDL-C were considered to be protective factors of vitamin D deficiency in PCOS women. These results suggest that PCOS women with metabolic risk factors are more likely to accompany vitamin D deficiency. Therefore, scholars from various countries have conducted randomized controlled trials on whether vitamin D supplementation can improve the metabolic risk factors of PCOS women. However, the results have been discordant. Vitamin D treatment improved the follicular development, menstrual cycle regulation, insulin resistance, and hyperandrogenism (21). However, Xue et al. showed that vitamin D supplementation did not change the HOMA-IR, LDL, DHEAS, free testosterone, and total testosterone in women with PCOS (31). The different results may be related to sample size, vitamin D supplement dose, participant habits, and place of residence. Therefore, multi-center randomized controlled trials with large sample sizes are needed to explore the metabolic role of vitamin D supplementation in women with PCOS.
This study has some limitations. The sample size of the participants was relatively small. In addition, this was a single-center study of PCOS women in the city of Xi'an in Shaanxi, China. Hence, the results of this research needs to be proved through multi-center surveys with large sample sizes in other areas in China.
Conclusion
Our data show that vitamin D deficiency is prevalent in PCOS women in Shaanxi China, especially in those with obesity and IR. The serum 25(OH)D concentration was correlated with metabolic risk factors in PCOS women. Multi-center randomized controlled trials with large sample sizes are needed to explore the metabolic role of vitamin D supplementation in women with PCOS.
Statements
Data availability statement
All datasets generated for this study are included in the article/supplementary material.
Ethics statement
The studies involving human participants were reviewed and approved by The First Affiliated Hospital of Xi'an Jiaotong University Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.
Author contributions
LW and XY conceived the study and wrote the manuscript. SL and FL collated data. XY and EB analyzed data. All authors have given final approval of the article to be published.
Funding
This study was supported by the basic research program of natural science of Shaanxi province, China (2019JM-569); the institutional foundation of the first affiliated hospital of Xi'an Jiaotong university (2019ZYTS-03).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
MarchWAMooreVMWillsonKJPhillipsDINormanRJDaviesMJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. (2010) 25:544–51. 10.1093/humrep/dep399
2.
The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. (2012) 27:14–24. 10.1093/humrep/der396
3.
LimSSDaviesMJNormanRJMoranLJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. (2012)18:618–37. 10.1093/humupd/dms030
4.
FauserBCTarlatzisBCRebarRWLegroRSBalenAHLoboRet al. Consensus on women's health aspects of polycystic ovary syndrome(PCOS): the Amsterdam ESHRE/ASRM-Sponsered 3rd PCOS Consensus Workshop Group. Fertil Steril. (2012) 97:28–38. 10.1016/j.fertnstert.2011.09.024
5.
Di DomenicoKWiltgenDNickelFJMagalhãesJAMoraesRSSpritzerPM. Cardiac autonomic modulation in polycystic ovary syndrome: does the phenotype matter?Fertil Steril. (2013) 99:286–92. 10.1016/j.fertnstert.2012.08.049.
6.
MoranLJMissoMLWildRANormanRJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. (2010)16:347–63. 10.1093/humupd/dmq001
7.
WildRARizzoMCliftonSCarminaE. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. (2011)95:1073–9.e1–11. 10.1016/j.fertnstert.2010.12.027
8.
BizzaroGAnticoAFortunatoABizzaroN. Vitamin D and autoimmune diseases: is vitamin D receptor (VDR) polymorphism the culprit?Isr Med Assoc J. (2017) 19:438–43. 10.4172/2168-9849.1000e105
9.
MohammadAMShammoNAJasemJA. Vitamin D status in acute myocardial infarction: a case-control study. Cardiovasc Endocrinol Metab. (2018) 7:93–6. 10.1097/XCE.0000000000000160
10.
SkaabyTThuesenBHLinnebergA. Vitamin D, cardiovascular disease and risk factors. Adv Exp Med Biol. (2017) 996:221–30. 10.1007/978-3-319-56017-5_18
11.
SassiFTamoneCD'AmelioP. Vitamin D: nutrient, hormone, and immunomodulator. Nutrients. (2018) 10:E1656. 10.3390/nu10111656
12.
LiHWBreretonREAndersonRAWallaceAMHoCK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. (2011) 60:1475–81. 10.1016/j.metabol.2011.03.002
13.
JohamAETeedeHJCassarSSteptoNKStraussBJHarrisonCLet al. Vitamin D in polycystic ovary syndrome: relationship to obesity and insulin resistance. Mol Nutr Food Res. (2016) 60:110–18. 10.1002/mnfr.201500259
14.
NgBKLeeCLLimPSOthmanHIsmailNAM. Comparison of 25-hydroxyvitamin D and metabolic parameters between women with and without polycystic ovarian syndrome. Horm Mol Biol Clin Investig. (2017) 31:j/hmbci.2017.31. 10.1515/hmbci-2016-0057
15.
ChenZJShiYSunYZhangBLiangXCaoYet al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. (2016) 375:523–33. 10.1056/NEJMoa1513873
16.
LiLZhangFCuiJShiYXiangJWangXet al. Association of betatrophin with metabolic characteristics in overweight/obese and lean women with PCOS. Gynecol Endocrinol. (2017) 33:238–43. 10.1080/09513590.2016.1252743
17.
JamilianMForoozanfardFRahmaniETalebiMBahmaniFAsemiZ. Effect of two different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome. Nutrients. (2017) 9:E1280. 10.3390/nu9121280
18.
YunCFChenJHeYMaoDWangRZhangYet al. Vitamin D deficiency prevalence and risk factors among pregnant Chinese women. Public Health Nutr. (2017) 20:1746–54. 10.1017/S1368980015002980
19.
HolickMF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. (2017) 18:153–65. 10.1007/s11154-017-9424-1
20.
ThomsonRLSpeddingSBuckleyJD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol. (2012) 77:343–50. 10.1111/j.1365-2265.2012.04434.x
21.
FangFNiKCaiYShangJZhangXXiongC. Effect of vitamin D supplementation on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract. (2017) 26:53–60. 10.1016/j.ctcp.2016.11.008
22.
Krul-PoelYHMKoendersPPSteegers-TheunissenRPBoekelETTerWeeMMLouwersYet al. Vitamin D and metabolic disturbances in polycystic ovary syndrome(PCOS): a cross-sectional study. PLoS ONE. (2018) 13:e0204748. 10.1371/journal.pone.0204748
23.
HeCLLinZMRobbSWEzeamamaAE. Serum vitamin D levels and polycystic ovary syndrome:a systematic review and meta-analysis. Nutrients. (2015)7:4555–77. 10.3390/nu7064555
24.
MuscogiuriGPolicolaCPriolettaASoriceGMezzaTLassandroAet al. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?Clin Nutr. (2012)31:476–80. 10.1016/j.clnu.2011.12.010
25.
TeegardenDDonkinSS. Vitamin D: emerging new roles in insulin sensitivity. Nutr Res Rev. (2009)22:82–92. 10.1017/S0954422409389301
26.
PittasAGLauJHuFBDawson-HughesB. The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. (2007) 92:2017–29. 10.1210/jc.2007-0298
27.
WehrEPilzSSchweighoferNGiulianiAKoperaDPieberTRet al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. (2009) 161:575–82. 10.1530/EJE-09-0432
28.
YildizhanRKurdogluMAdaliEKolusariAYildizhanBSahinHGet al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. (2009) 280:559–63. 10.1007/s00404-009-0958-7
29.
ChagasCEBorgesMCMartiniLARogeroMM. Focus on vitamin D, inflammation and type 2 diabetes. Nutrients. (2012) 4:52–67. 10.3390/nu4010052
30.
MaktabiMChamaniMAsemiZ. The effects of vitamin D supplementation on metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Horm Metab Res. (2017) 49:493–8. 10.1055/s-0043-107242
31.
XueYPXuPXueKDuanXCaoJLuanTet al. Effect of vitamin D on biochemical parameters in polycystic ovary syndrome women: a meta-analysis. Arch Gynecol Obstet. (2017) 295:487–96. 10.1007/s00404-016-4247-y
Summary
Keywords
vitamin D deficiency, metabolic disturbances, polycystic ovary syndrome, obesity, insulin resistance, Shaanxi China
Citation
Wang L, Lv S, Li F, Yu X, Bai E and Yang X (2020) Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China. Front. Endocrinol. 11:171. doi: 10.3389/fendo.2020.00171
Received
12 December 2019
Accepted
10 March 2020
Published
31 March 2020
Volume
11 - 2020
Edited by
Daniele Santi, University of Modena and Reggio Emilia, Italy
Reviewed by
Ljiljana Marina, University of Belgrade, Serbia; Ludwig Wildt, Innsbruck Medical University, Austria
Updates
Copyright
© 2020 Wang, Lv, Li, Yu, Bai and Yang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaofeng Yang yxf73@163.com
This article was submitted to Reproduction, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.